Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Daclatasvir

Unbound Apparent Clearance (CLU/F) of Daclatasvir

Unbound Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity Time (AUC(INF)u) of Daclatasvir

Maximum Observed Plasma Concentration (Cmax) of Daclatasvir

Unbound Maximum Observed Plasma Concentrations of Daclatasvir

Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration [AUC(0-T)] of Daclatasvir

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Daclatasvir

Plasma Half-life (T-half) of Daclatasvir

Apparent Total Body Clearance (CLT/F) of Daclatasvir

Percent Urinary Recovery (%UR) of Daclatasvir

Renal Clearance (CLR) of Daclatasvir

Apparent Volume of Distribution (Vd/F) of Daclatasvir

Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events and Who Died

Number of Participants With Clinically Significant Laboratory Marked Abnormalities Reported as Adverse Events

Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Reported as Adverse Events

Number of Participants With Out-of-range Vital Signs Reported as Adverse Events